Loading...
•
Jun 30, 2021
Innoviva Q2 2021 Earnings Report
Reported financial results demonstrating royalty revenues growth and strategic investments.
Key Takeaways
Innoviva reported a 44% year-over-year growth in royalty revenues, driven by the strength and resilience of its respiratory assets partnered with Glaxo Group Limited (GSK). The company deployed over $400 million in strategic investments and executed on its strategy of creating shareholder value through operational excellence.
Royalty revenues increased by 44% year-over-year.
RELVAR®/BREO® ELLIPTA® global net sales increased significantly, with U.S. net sales driven by a favorable adjustment and non-U.S. sales increasing by 13%.
ANORO® ELLIPTA® global net sales increased by 7%, with non-U.S. sales increasing by 25%.
TRELEGY® ELLIPTA® global net sales increased by 69%, driven by strong volume growth and a favorable adjustment in the U.S. as well as strong launches in non-U.S. markets.
Forward Guidance
This press release contains forward-looking statements regarding goals, plans, objectives, and future events, which are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...